Sophiris Bio Inc. (SPHS)

Oncology Corporate Profile

Stock Performance

1.2500
-0.0300

HQ Location

1258 Prospect Street
La Jolla, CA 92037

Company Description

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer.

Website: http://www.sophirisbio.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
topsalysin / PRX302prostate-specific antigen (PSA) inhibitorProstate cancerII

View additional information on product candidates here »

Source: http://www.sophirisbio.com/

Recent News Headlines

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/18/2017 12:19 pm

5/18/2017 12:19 pm

5/18/2017 12:19 pm

5/18/2017 12:19 pm

5/15/2017 12:19 pm

5/15/2017 12:19 pm

5/15/2017 12:19 pm

5/15/2017 12:19 pm

5/15/2017 12:19 am

5/15/2017 12:19 am

5/15/2017 12:19 am

Sophiris Bio to Present at 16th Annual Needham Healthcare Conference

3/29/2017 08:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 29, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference. The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophirisbio.com.

Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights

3/27/2017 01:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ...

Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress

3/23/2017 08:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ...

Sophiris Bio to Present at 29th Annual ROTH Conference

3/6/2017 09:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 6, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 29th Annual ROTH Conference. The presentation is scheduled for Monday, March 13, 2017 at 5:00 p.m. PDT at The Ritz-Carlton, Dana Point, California. The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophiris.com.

Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference

1/30/2017 09:00 pm

[CNW Group] - Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference

Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference

1/30/2017 09:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, Jan. 30, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the BetterInvesting™ Virtual Investor Conference. The presentation will take place on Thursday February 2, 2017 at 1:00 p.m. Eastern Time. The presentation will be webcast live at http://tinyurl.com/0202prepr and can also be accessed through the Investor Relations page at www.sophiris.com.

Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd

1/30/2017 07:01 pm

[CNW Group] - Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd